Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to ...

As the U.S. equities market takes a breather from its recent rally, major indices like the S&P 500 have reached new highs, reflecting investor optimism amid strong corporate earnings and pro-business ...

Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to ...

The researchers said the findings from the world-first study were “deeply concerning” while other experts said the research ...

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research ...

In a challenging market environment, 4D Molecular Therapeutics (FDMT) stock has reached a new 52-week low, dipping to $4.48, ...

The Honourable Soraya Martinez Ferrada, Minister of Tourism and Minister responsible for CED, along with Stéphane Lauzon, Member of Parliament ...

Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of 4D Molecular ...

D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC ...

4D Molecular Therapeutics (NASDAQ:FDMT) finds itself at a critical juncture as it advances its gene therapy pipeline targeting large markets in ophthalmology and rare diseases. According to ...

On Monday, BMO Capital Markets issued a downgrade for 4D Molecular Therapeutics (NASDAQ:FDMT) from Outperform to Market Perform, setting a price target of $15.00. The stock, currently trading at $5.52 ...

The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.